TITLE

Treatment modalities for hypersplenism in liver transplant recipients with recurrent hepatitis C

AUTHOR(S)
Sibulesky, Lena; Nguyen, Justin H.; Paz-Fumagalli, Ricardo; Taner, C. Burcin; Dickson, Rolland C.; Kwo, Paul Y.
PUB. DATE
October 2009
SOURCE
World Journal of Gastroenterology;10/28/2009, Vol. 15 Issue 40, p5010
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Hepatitis C is the most common indication for orthotopic liver transplantation in the United States. Unfortunately, hepatitis C recurs universally in the transplanted liver and is the major cause of decreased graft and patient survival. The combination therapy of interferon and ribavirin has been shown to be the most effective therapy for recurrent hepatitis C. However, pre- and post-transplant hypersplenism often precludes patients from receiving the antiviral therapy. Splenectomy and partial splenic embolization are the two invasive modalities that can correct the cytopenia associated with hypersplenism. In this report we review the two treatment options, their associated outcomes and complications.
ACCESSION #
44922482

 

Related Articles

  • Race Affects Hepatitis C Recurrence After Liver Transplant: study.  // Tennessee Tribune;11/4/2010, Vol. 21 Issue 44, p11B 

    The article presents information on a study on Hepatitis C at Henry Ford Hospital in Detroit, Michigan, according to which race of liver donor affects the recurrence of Hepatitis C after liver transplantation.

  • HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: IS THERE CAUSE FOR CONCERN? Sorrell, Michael F. // American Journal of Gastroenterology;Sep1997, Vol. 92 Issue 9, p1416 

    Discusses the recurrence of hepatitis C after undergoing a liver transplant. Percentage of patients who developed a chronic hepatitis after transplantation; Increase in hepatitis C virus RNA levels after transplantation; Background on a study by Rosen et al regarding the role of murine...

  • Molecular Pathways Differentiate Hepatitis C Virus (HCV) Recurrence from Acute Cellular Rejection in HCV Liver Recipients. Gehrau, Ricardo; Maluf, Daniel; Archer, Kellie; Stravitz, Richard; Suh, Jihee; Le, Ngoc; Mas, Valeria // Molecular Medicine;Jul/Aug2011, Vol. 17 Issue 7/8, p824 

    Acute cellular rejection (ACR) and hepatitis C virus (HCV) recurrence (HCVrec) are common complications after liver transplantation (LT) in HCV patients, who share common clinical and histological features, making a differential diagnosis difficult. Fiftythree liver allograft samples from unique...

  • Recurrence of Diseases Following Orthotopic Liver Transplantation. Kotlyar, David S.; Campbell, Mical S.; Reddy, K. Rajender // American Journal of Gastroenterology;Jun2006, Vol. 101 Issue 6, p1370 

    Long-term graft survival and mortality after liver transplantation continue to improve. However, disease recurrence remains a major stumbling block, especially among patients with hepatitis C. Chronic hepatitis C recurs to varying degrees in nearly all patients who undergo transplantation....

  • Recurrent Hepatitis C After Liver Transplant: Survival Unchanged. McCashland, Timothy M.; Thompson, Jon S. // American Journal of Gastroenterology;May1998, Vol. 93 Issue 5, p683 

    Discusses research being done on the recurrence of hepatitis C infection following liver transplantation. Reference to a study by Shuhart and colleagues, published in a 1997 issue of the "Hepatology"; Comparison between the cumulative survival rate of HCV recipients and liver transplant...

  • Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation. Tomohide Hori; Yasuharu Onishi; Hideya Kamei; Nobuhiko Kurata; Masatoshi Ishigami; Yoji Ishizu; Yasuhiro Ogura // Annals of Gastroenterology;2016, Vol. 29 Issue 4, p454 

    Hepatitis C recurrence continues to present a major challenge in liver transplantation (LT). Approximately 10% of hepatitis C virus (HCV)-positive recipients will develop fibrosing cholestatic hepatitis (FCH) after LT. FCH is clinically characterized as marked jaundice with cholestatic hepatic...

  • Living donor liver transplantation for hepatitis C. Takada, Yasutsugu; Uemoto, Shinji // Surgery Today;Jul2013, Vol. 43 Issue 7, p709 

    Liver cirrhosis and hepatocellular carcinoma related to chronic hepatitis C virus (HCV) infection are currently the most common indications for liver transplantation. The number of living donor liver transplantation (LDLT) procedures has increased given the shortage of donor organs from deceased...

  • Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation. Issa, D.; Eghtesad, B.; Zein, N. N.; Yerian, L.; Cruise, M.; Alkhouri, N.; Adams, R.; Hanouneh, I. A. // International Journal of Organ Transplantation Medicine;2016, Vol. 7 Issue 1, p38 

    Fibrosing cholestatic hepatitis (FCH) is an aggressive form of hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT), which frequently results in graft failure and death. Treatment of FCH remains challenging, and the optimal antiviral therapy is yet to be determined....

  • Recurrent Hepatitis C After Liver Transplantation. Khara, Harshit; Mukherjee, Sandeep // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Jun2010, Vol. 10 Issue 2, p91 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics